1,2,3-triazole and chiral Schiff base hybrids as potential anticancer agents: DFT, molecular docking and ADME studies

Yonas Belay, Alfred Muller, Fanikie S. Mokoena, Adedapo S. Adeyinka, Lesetja R. Motadi, Abel K. Oyebamiji

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

A series of novel 1,2,3-triazole and chiral Schiff base hybrids 2–6 were synthesized by Schiff base condensation reaction from pre-prepared parent component of the hybrids (1,2,3-triazole 1) and series of primary chiral amines and their chemical structure were confirmed using NMR and FTIR spectroscopies, and CHN elemental analysis. Compounds 1–6 were evaluated for their anticancer activity against two cancer PC3 (prostate) and A375 (skin) and MRC-5 (healthy) cell lines by Almar Blue assay method. The compounds exhibited significant cytotoxicity against the tested cancer cell lines. Among the tested compounds 3 and 6 showed very good activity for the inhibition of the cancer cell lines and low toxicity for the healthy cell lines. All the compounds exhibited high binding affinity for Androgen receptor modulators (PDB ID: 5t8e) and Human MIA (PDB ID: 1i1j) inhibitors compared to the reference anticancer drug (cisplatin). Structure activity relationships (SARs) of the tested compounds is in good agreement with DFT and molecular docking studies. The compounds exhibited desirable physicochemical properties for drug likeness.

Original languageEnglish
Article number6951
JournalScientific Reports
Volume14
Issue number1
DOIs
Publication statusPublished - Dec 2024

Keywords

  • 1,2,3-triazole
  • ADME
  • Cancer
  • Chiral Schiff bases
  • Hybrid drugs
  • Molecular docking

ASJC Scopus subject areas

  • Multidisciplinary

Fingerprint

Dive into the research topics of '1,2,3-triazole and chiral Schiff base hybrids as potential anticancer agents: DFT, molecular docking and ADME studies'. Together they form a unique fingerprint.

Cite this